A novel signature predicts recurrence risk and therapeutic response in breast cancer patients-Reference-Cited by-同舟云学术

A novel signature predicts recurrence risk and therapeutic response in breast cancer patients

Published:2021-02-21 Issue:11 Volume:148 Page:2848-2856
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Tran Quynh Hoa¹,Than Van Thai²³,Luu Phuc Loi⁴,Clarke Declan⁵⁶,Lam Hanh Ngoc⁷,Nguyen Thanh‐Giang Tan⁸,Nguyen Dinh‐Truong⁸,Duy Phan Q.⁹,Phung Dung¹⁰,Nguyen Minh Nam¹¹^ORCID

Affiliation:

1. Department of Biotechnology Ho Chi Minh City University of Food Industry Ho Chi Minh City Vietnam

2. Faculty of Biotechnology, Chemistry and Environmental Engineering PHENIKAA University Hanoi Vietnam

3. PHENIKAA Research and Technology Institute (PRATI) A&A Green Phoenix Group JSC Hanoi Vietnam

4. Epigenetics Research Laboratory Genomics and Epigenetics Division, Garvan Institute of Medical Research Darlinghurst New South Wales Australia

5. Program in Computational Biology and Bioinformatics Yale University New Haven Connecticut USA

6. Department of Molecular Biophysics and Biochemistry Yale University New Haven Connecticut USA

7. Department of Microbiology and Environmental Toxicology University of California Santa Cruz California USA

8. School of Biotechnology Tan Tao University Tan Duc E.City Vietnam

9. Medical Scientist Training Program Yale University School of Medicine New Haven Connecticut USA

10. School of Medicine Griffith University Southport Queensland Australia

11. School of Medicine Vietnam National University Ho Chi Minh City Ho Chi Minh City Vietnam

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33512

Reference36 articles.

1. Cancer statistics, 2018

2. Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

3. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

4. Melatonin: an inhibitor of breast cancer

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive study on epigenetic signatures to monitor disease progression and the response to therapy in breast cancer;Biomedical Analysis;2024-09

2. Interplay between gut microbial composition and the melatonergic pathway: implications for hormonal receptor-positive breast cancer development;2024-05-13

3. Melatonin Reverses the Warburg-Type Metabolism and Reduces Mitochondrial Membrane Potential of Ovarian Cancer Cells Independent of MT1 Receptor Activation;Molecules;2022-07-07

4. The Intricate Relationship between Melatonin and Breast Cancer: A Short Review;Chirurgia;2021